Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Standard

Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. / Schiellerup, Sine Paasch; Skov-Jeppesen, Kirsa; Windelov, Johanne Agerlin; Svane, Maria Saur; Holst, Jens Juul; Hartmann, Bolette; Rosenkilde, Mette Marie.

I: Frontiers in Endocrinology, Bind 10, 75, 2019.

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Harvard

Schiellerup, SP, Skov-Jeppesen, K, Windelov, JA, Svane, MS, Holst, JJ, Hartmann, B & Rosenkilde, MM 2019, 'Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment', Frontiers in Endocrinology, bind 10, 75. https://doi.org/10.3389/fendo.2019.00075

APA

Schiellerup, S. P., Skov-Jeppesen, K., Windelov, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & Rosenkilde, M. M. (2019). Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Frontiers in Endocrinology, 10, [75]. https://doi.org/10.3389/fendo.2019.00075

Vancouver

Schiellerup SP, Skov-Jeppesen K, Windelov JA, Svane MS, Holst JJ, Hartmann B o.a. Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Frontiers in Endocrinology. 2019;10. 75. https://doi.org/10.3389/fendo.2019.00075

Author

Schiellerup, Sine Paasch ; Skov-Jeppesen, Kirsa ; Windelov, Johanne Agerlin ; Svane, Maria Saur ; Holst, Jens Juul ; Hartmann, Bolette ; Rosenkilde, Mette Marie. / Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. I: Frontiers in Endocrinology. 2019 ; Bind 10.

Bibtex

@article{435ba7edfbb84058af1a59ee30b6952c,
title = "Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment",
abstract = "Bone homeostasis displays a circadian rhythm with increased resorption during the night time as compared to day time, a difference that seems-at least partly-to be caused by food intake during the day. Thus, ingestion of a meal results in a decrease in bone resorption, but people suffering from short bowel syndrome lack this response. Gut hormones, released in response to a meal, contribute to this link between the gut and bone metabolism. The responsible hormones appear to include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part of this gut-bone axis. Several studies, including human studies, have indicated that these three hormones inhibit bone resorption and, moreover, that GIP increases bone formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent studies have also shown an effect of PYY on bone metabolism. The aim of this review is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future therapies targeting these receptors for the treatment of osteoporosis.",
keywords = "gut hormones, bone metabolism, GIP, GLP-1, GLP-2, PYY, osteoporosis",
author = "Schiellerup, {Sine Paasch} and Kirsa Skov-Jeppesen and Windelov, {Johanne Agerlin} and Svane, {Maria Saur} and Holst, {Jens Juul} and Bolette Hartmann and Rosenkilde, {Mette Marie}",
year = "2019",
doi = "10.3389/fendo.2019.00075",
language = "English",
volume = "10",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment

AU - Schiellerup, Sine Paasch

AU - Skov-Jeppesen, Kirsa

AU - Windelov, Johanne Agerlin

AU - Svane, Maria Saur

AU - Holst, Jens Juul

AU - Hartmann, Bolette

AU - Rosenkilde, Mette Marie

PY - 2019

Y1 - 2019

N2 - Bone homeostasis displays a circadian rhythm with increased resorption during the night time as compared to day time, a difference that seems-at least partly-to be caused by food intake during the day. Thus, ingestion of a meal results in a decrease in bone resorption, but people suffering from short bowel syndrome lack this response. Gut hormones, released in response to a meal, contribute to this link between the gut and bone metabolism. The responsible hormones appear to include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part of this gut-bone axis. Several studies, including human studies, have indicated that these three hormones inhibit bone resorption and, moreover, that GIP increases bone formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent studies have also shown an effect of PYY on bone metabolism. The aim of this review is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future therapies targeting these receptors for the treatment of osteoporosis.

AB - Bone homeostasis displays a circadian rhythm with increased resorption during the night time as compared to day time, a difference that seems-at least partly-to be caused by food intake during the day. Thus, ingestion of a meal results in a decrease in bone resorption, but people suffering from short bowel syndrome lack this response. Gut hormones, released in response to a meal, contribute to this link between the gut and bone metabolism. The responsible hormones appear to include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part of this gut-bone axis. Several studies, including human studies, have indicated that these three hormones inhibit bone resorption and, moreover, that GIP increases bone formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent studies have also shown an effect of PYY on bone metabolism. The aim of this review is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future therapies targeting these receptors for the treatment of osteoporosis.

KW - gut hormones

KW - bone metabolism

KW - GIP

KW - GLP-1

KW - GLP-2

KW - PYY

KW - osteoporosis

U2 - 10.3389/fendo.2019.00075

DO - 10.3389/fendo.2019.00075

M3 - Review

C2 - 30863364

VL - 10

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 75

ER -

ID: 216927913